Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL

expresspharmaSeptember 08, 2020

Tag: Janssen , Imbruvica , EC , CLL

PharmaSources Customer Service